Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
BackgroundReport of the task force on designing clinical trials in early (predementia) AD
Aisen, P. S., Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z. S., Dubois, B., Feldman, H. H., Petersen, R. C., Siemers, E., Doody, R. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318207b1b9 · Cited by 172 · cited 1×
“It has been suggested that use of antiamyloid agents may be optimized by intervening earlier in the disease process before nonamyloid processes prevail and neurodegeneration begins [20-23].”
BackgroundTasneem, A., Aberle, L., Ananth, H., Chakraborty, S., Chiswell, K., McCourt, B. J., & Pietrobon, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033677 · Cited by 166 · cited 1×
“gov (AACT), has become available [12] and may facilitate further analyses.”
BackgroundAdvances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis
Dong, S., Duan, Y., Hu, Y., & Zhao, Z. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-18 · Cited by 165 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundEvaluation of Drugs With Specific Organ Toxicities in Organ-Specific Cell Lines
Lin, Z., & Will, Y. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfr339 · Cited by 158 · cited 1×
“New means of predicting drug toxicity may reduce the attrition rate attributable to lack of safety [18,19].”
BackgroundOf Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery
Geerts, H. (2009) · CNS Drugs · doi:10.2165/11310890-000000000-00000 · Cited by 149
Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress
Castellani, R. J., & Perry, G. L. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.009 · Cited by 113
Hyde, C., Peters, J., Bond, M., Rogers, G., Hoyle, M., Anderson, R., Jeffreys, M., Davis, S., Thokala, P., & Moxham, T. (2012) · Age and Ageing · doi:10.1093/ageing/afs165 · Cited by 111 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.027 · Cited by 84 · cited 1×
“Many animal models of amyloidosis have shown biological and behavioral benefit from anti-Aβ agents, creating a “translational gap” between human and animal studies [27-30].”
BackgroundSelf-citationMapping the Road Forward in Alzheimer’s Disease
Holtzman, D. M., Goate, A., Kelly, J. W., & Sperling, R. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003529 · Cited by 82 · cited 1×
“It has been suggested that use of antiamyloid agents may be optimized by intervening earlier in the disease process before nonamyloid processes prevail and neurodegeneration begins [20-23].”
BackgroundMoving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease
Aisen, P. S. S., Vellas, B. J., & Hampel, H. J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3842-c1 · Cited by 81 · cited 1×
“It has been suggested that use of antiamyloid agents may be optimized by intervening earlier in the disease process before nonamyloid processes prevail and neurodegeneration begins [20-23].”
BackgroundCummings, J. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.020 · Cited by 65 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
BackgroundSelf-citationModeling an Anti-Amyloid Combination Therapy for Alzheimer’s Disease
Chow, V. W., Savonenko, A. V., Melnikova, T., Kim, H., Price, D. L., Li, T., & Wong, P. C. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000337 · Cited by 53 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundDrug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 50
Vellas, B. J., Hampel, H. J., Bugat, M.-È. R., Grundman, M., Andrieu, S., Abushakra, S. R., Bateman, R. J., Berman, R., Black, R. S., Carrillo, M. C., et al. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0044-x · Cited by 45 · cited 1×
“It has been suggested that use of antiamyloid agents may be optimized by intervening earlier in the disease process before nonamyloid processes prevail and neurodegeneration begins [20-23].”
BackgroundGlobalization of Alzheimer's disease clinical trials
Cummings, J. L., Reynders, R., & Zhong, K. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt86 · Cited by 39 · cited 1×
“The reasons for trial failures suggest means of enhancing the success of trials, including improved rating strategies, enhanced training, and better patient-selection approaches [16,17].”
BackgroundSelf-citationXie, H., Wang, S., Cao, C., & Harpur, E. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.004 · Cited by 29 · cited 1×
“New means of predicting drug toxicity may reduce the attrition rate attributable to lack of safety [18,19].”
BackgroundIncreasing the success rate for Alzheimer's disease drug discovery and development
Becker, R. E., & Greig, N. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.672409 · Cited by 27 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
BackgroundWas Phenserine a Failure or Were Investigators Mislead by Methods?
Becker, R. E., & Greig, N. H. (2012) · Current Alzheimer Research · doi:10.2174/156720512804142912 · Cited by 22 · cited 1×
“The reasons for trial failures suggest means of enhancing the success of trials, including improved rating strategies, enhanced training, and better patient-selection approaches [16,17].”
BackgroundThe Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
Wilcock, D. M. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791556168 · Cited by 17 · cited 1×
“Many animal models of amyloidosis have shown biological and behavioral benefit from anti-Aβ agents, creating a “translational gap” between human and animal studies [27-30].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
“gov, a National Institutes of Health registry of publicly and privately funded clinical studies [106].”
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
“gov, a National Institutes of Health registry of publicly and privately funded clinical studies [133].”
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
